Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 8/20 | 0.41 |
| ▸ | NOS2 | P35228 | 8/20 | 0.41 |
| ▸ | NOS1 | P29475 | 7/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | CD44 | P16070 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21287270 | 0.81 | NOS3 (0.41) | NOS3NOS2NOS1BACE1PRMT5 | |
| SCHEMBL21223482 | 0.77 | NOS3 (0.38) | NOS3NOS2NOS1BACE1PRMT5 | |
| SCHEMBL22029192 | 0.77 | NOS3 (0.38) | NOS3NOS2NOS1BACE1PRMT5 | |
| SCHEMBL30915338 | 0.77 | NOS3 (0.38) | NOS3NOS2NOS1BACE1PRMT5 | |
| SCHEMBL10411734 | 0.75 | SMN1; SMN2 (0.54) | PDE10APOLBALDH1A1GAA | |
| SCHEMBL3673476 | 0.75 | NOS2 (0.48) | NOS3NOS2NOS1BACE1PRMT5 | |
| SCHEMBL31396216 | 0.75 | ALDH1A1 (0.39) | PDE10APOLBCYP3A4ALDH1A1 | |
| SCHEMBL11985859 | 0.75 | ALDH1A1 (0.39) | PDE10APOLBCYP3A4ALDH1A1 | |
| SCHEMBL4646183 | 0.75 | NOS2 (0.43) | NOS3NOS2NOS1BACE1PRMT5 | |
| SCHEMBL22063663 | 0.74 | NOS2 (0.42) | NOS3NOS2NOS1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044667-A2 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20230373939-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373939-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373939-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-23 | — | — | US | disclosed |
| EP-4225737-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076628-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-2789606-B1 | Modulators of CFTR | VERTEX PHARMA (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2789606-B1 | Modulators of CFTR | VERTEX PHARMA (US) | 2017-11-15 | — | — | EP | disclosed |
| US-9725440-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725440-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150031708-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-29 | — | — | US | disclosed |
| US-20150031708-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-29 | — | — | US | disclosed |
| US-20150031708-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-29 | — | — | US | disclosed |
| EP-2789606-A1 | Modulators of CFTR | Vertex Pharmaceuticals Incorporated (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2789606-A1 | Modulators of CFTR | Vertex Pharmaceuticals Incorporated (US) | 2014-10-15 | — | — | EP | disclosed |
| CN-102863432-A | Modulators of cftr | VERTEX PHARMA | 2013-01-09 | — | — | CN | disclosed |
| CN-101687842-A | modulators of cftr | VERTEX PHARMA | 2010-03-31 | — | — | CN | disclosed |
| EP-2164840-A2 | MODULATORS OF CFTR | Vertex Pharmaceuticals Incorporated (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008141119-A2 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008141119-A2 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031708-A1 | MODULATORS OF CFTR | CFTR, ABCB1, ABCC4 | NOS3 4373/4885NOS2 4597/4885NOS1 4565/4885 |
| US-20230373939-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | NOS3 4316/4885NOS2 4519/4885NOS1 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.